BioXcel Therapeutics Financials
BTAI Stock | USD 0.43 0.02 4.88% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.51 | 2.6458 |
|
|
Investors should never underestimate BioXcel Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BioXcel Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in BioXcel Therapeutics.
Net Income |
|
BioXcel | Select Account or Indicator |
Understanding current and past BioXcel Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioXcel Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in BioXcel Therapeutics' assets may result in an increase in income on the income statement.
BioXcel Therapeutics Stock Summary
BioXcel Therapeutics competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, and X4 Pharmaceuticals. BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Bioxcel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US09075P1057 |
CUSIP | 09075P105 |
Location | Connecticut; U.S.A |
Business Address | 555 Long Wharf |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.bioxceltherapeutics.com |
Phone | 475 238 6837 |
Currency | USD - US Dollar |
BioXcel Therapeutics Key Financial Ratios
Return On Equity | -17.67 | ||||
Operating Margin | (14.89) % | ||||
Price To Sales | 9.10 X | ||||
Revenue | 1.38 M | ||||
Gross Profit | 355 K |
BioXcel Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 36.4M | 219.9M | 239.4M | 205.9M | 73.7M | 100.3M | |
Total Liab | 9.5M | 13.2M | 17.8M | 129.1M | 130.2M | 136.7M | |
Total Current Assets | 34.1M | 217.1M | 233.0M | 202.9M | 72.1M | 98.2M | |
Other Current Liab | 3.5M | 6.9M | 11.4M | 22.3M | 13.2M | 8.5M | |
Net Tangible Assets | 26.9M | 206.7M | 221.7M | 76.8M | 88.3M | 89.5M | |
Retained Earnings | (56.7M) | (138.9M) | (245.8M) | (411.5M) | (590.6M) | (561.1M) | |
Accounts Payable | 5.0M | 4.0M | 4.7M | 10.2M | 13.7M | 14.3M | |
Cash | 32.4M | 213.1M | 233.0M | 193.7M | 65.2M | 107.4M | |
Other Current Assets | 1.7M | 6.9M | 3.8M | 6.9M | 4.9M | 3.4M | |
Common Stock | 16K | 18K | 24K | 28K | 30K | 31.5K | |
Net Debt | (31.4M) | (211.5M) | (231.6M) | (99.6M) | 36.2M | 38.0M | |
Capital Surpluse | 83.6M | 345.5M | 467.4M | 488.3M | 561.5M | 589.6M | |
Net Invested Capital | 26.9M | 206.7M | 221.7M | 169.8M | 44.1M | 41.9M | |
Net Working Capital | 25.6M | 205.2M | 220.1M | 170.0M | 44.9M | 42.6M |
BioXcel Therapeutics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Operating Income | (33.6M) | (82.3M) | (106.9M) | (159.6M) | (171.8M) | (163.2M) | |
Income Before Tax | (33.0M) | (82.2M) | (106.9M) | (165.8M) | (179.1M) | (170.1M) | |
Net Income | (32.3M) | (82.0M) | (106.6M) | (171.8M) | (179.1M) | (170.1M) | |
Gross Profit | (156K) | 24.3 | (297K) | 355K | 120K | 126K | |
Ebit | (33.6M) | (82.3M) | (106.9M) | (157.7M) | (165.7M) | (157.5M) | |
Research Development | 25.8M | 58.0M | 52.7M | 91.2M | 84.3M | 45.5M | |
Ebitda | (34.1M) | (82.1M) | (106.6M) | (157.4M) | (165.4M) | (157.1M) | |
Cost Of Revenue | 156K | 188K | 297K | 20K | 1.3M | 1.3M | |
Income Tax Expense | (633K) | (161K) | (301K) | 6.1M | 150.1K | 142.6K | |
Interest Income | 633K | 155K | 44K | 2.5M | 6.2M | 6.5M |
BioXcel Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Capital Expenditures | 870K | 316K | 445K | 139K | 20K | 19K | |
Net Income | (33.0M) | (82.2M) | (106.9M) | (165.8M) | (179.1M) | (170.1M) | |
Investments | (870K) | (316K) | (445K) | (139K) | (20K) | (21K) | |
Change In Cash | (10.1M) | 180.7M | 19.8M | (39.2M) | (128.5M) | (122.1M) | |
Net Borrowings | (371K) | 179K | 98.6M | 96.0M | 110.3M | 115.9M | |
Free Cash Flow | (28.2M) | (66.7M) | (82.6M) | (135.5M) | (155.0M) | (147.3M) | |
Depreciation | 156K | 188K | 297K | 327K | 318K | 179.3K | |
Change To Netincome | 3.1M | 14.6M | 19.5M | 18.6M | 21.3M | 22.4M | |
Other Non Cash Items | 3.5M | 15.0M | 46K | 2.1M | 3.1M | 3.3M | |
End Period Cash Flow | 32.4M | 213.1M | 233.0M | 193.7M | 65.2M | 122.7M |
BioXcel Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioXcel Therapeutics's current stock value. Our valuation model uses many indicators to compare BioXcel Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioXcel Therapeutics competition to find correlations between indicators driving BioXcel Therapeutics's intrinsic value. More Info.BioXcel Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, BioXcel Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioXcel Therapeutics' earnings, one of the primary drivers of an investment's value.BioXcel Therapeutics Systematic Risk
BioXcel Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioXcel Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on BioXcel Therapeutics correlated with the market. If Beta is less than 0 BioXcel Therapeutics generally moves in the opposite direction as compared to the market. If BioXcel Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioXcel Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioXcel Therapeutics is generally in the same direction as the market. If Beta > 1 BioXcel Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in BioXcel Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioXcel Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BioXcel Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
BioXcel Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioXcel Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioXcel Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioXcel Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing BioXcel Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioXcel Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.09) | |||
Maximum Drawdown | 39.77 | |||
Value At Risk | (8.89) | |||
Potential Upside | 9.62 |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Stocks Directory Find actively traded stocks across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |